Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications

导出原文传递

翻译打印收藏纠错

作者： Rathkopf, Dana E. ^[1] ; Larson, Steven M. ^[2] ; Anand, Aseem ^[3] ; Morris, Michael J. ^[4] ; Slovin, Susan F. ^[5] ; Shaffer, David R. ^[6] ; Heller, Glenn ; Carver, Brett ; Rosen, Neal ; Scher, Howard I.

作者单位： Weill Cornell Med Coll, New York, NY USA ^[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA ^[2] New York Oncol Hematol, Albany, NY USA ^[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA ^[4] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, New York, NY 10065 USA ^[5] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA ^[6]

关键词 mammalian target of rapamycin (mTOR)pharmacokinetics prostatic neoplasms quinazolines (gefitinib)sirolimus derivatives (everolimus)target of rapamycin (TOR) serine-threonine kinases

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交